A five-target mRNA- cocktail vaccine showed stronger immune and protective effects against Staphylococcus aureus than comparator vaccines in mice.
Evidence
This preclinical mouse study compared monovalent mRNA-LNPs, a multivalent mRNA-LNP cocktail, and a protein cocktail for humoral and cellular responses, survival, bacterial load, and organ damage.
Caveat
The evidence is limited to murine infection models, so it does not establish human protection or clinical safety against Staphylococcus aureus.
Simplified
Staphylococcus aureus has been posing a significant global health threat, underscoring an urgent need for innovative preventive strategies, notably vaccines. This study presents an evaluation of a multi-target against S. aureus, engineered to target five pivotal virulence factors: the manganese transporter MntC, enterotoxin SEB, exotoxin HLA, adhesion factor FnBPA, and iron surface binding protein IsdB. In a parallel control setting, mice were immunized with either monovalent mRNA-, a multivalent mRNA-LNP cocktail, or a protein cocktail, and were subsequently assessed for humoral and cellular immune responses as well as the vaccines' protective efficacy. The findings demonstrated that the multivalent mRNA-LNP cocktail vaccine induced a robust and sustained humoral immune response, along with a stronger cellular immune response compared to both monovalent mRNA vaccines and the protein cocktail vaccine. This was characterized by increased secretion of IFN-γ, IL-2, IL-4, and IL-17A, suggesting a potent Th1/Th2/Th17 mixed immune response. Moreover, the cocktail vaccine demonstrated improved survival rates and a reduction in bacterial loads and organ damage. These results underscore the promise of a multi-target mRNA vaccine strategy in combating antibiotic-resistant Staphylococcus aureus.
Key numbers
higher than monovalent vaccines
Increase in Titers
Compared to monovalent mRNA vaccines.
higher than monovalent and protein-based vaccines
Survival Rate
In murine models post-challenge.
Full Text
We can’t show the full text here under this license.
mRNA Technology